Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03963375 · ClinicalTrials.gov registry record · Phase 4
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
A Phase 4 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT03963375 is a Phase 4 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 47 participants.
The verdict
NCT03963375, a Phase 4 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS \[RRMS\] or active secondary progressive MS).
Interventions
- DRUG Cladribine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2025-05-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03963375
The ClinicalTrials.gov registry entry for NCT03963375 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cladribine is the first listed.
NCT03963375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03963375 about?
NCT03963375 is a clinical study titled "Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis". The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS \[RRMS\] or active secondar...
What is the current status of trial NCT03963375?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2019-10-28. Estimated completion is 2025-05-27.
What interventions are being tested in trial NCT03963375?
The interventions under investigation include: Cladribine (DRUG).
Who is sponsoring clinical trial NCT03963375?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.